Pharmaceutical Pricing Policies in Norway and Sweden

Chapter

Abstract

This chapter provides an overview of the organization of pricing, reimbursement of medicines, and the organization of the pharmaceutical systems in the two Scandinavian countries Norway and Sweden. The two countries have many similarities; however, they have also chosen different roads in several aspects. Both countries have a comprehensive tax-based public health insurance covering health services for all inhabitants. This includes medicines provided to cure, alleviate or prevent diseases that have been judged to be in the interest of the public. Pricing of prescribed medicines is strictly regulated in the two countries. More than 70 % of the total pharmaceutical expenditures are paid by a public third-party payer. Both countries experienced dramatic increase in pharmaceutical expenditures in the early 1990s. This set off a series of reforms concerning the pricing and reimbursement of medicines. The fundamental principle for pricing of prescription medicines is maximum pricing at the retail level. Norway applies international reference pricing while Sweden’s pricing system is based on health economic evaluations. Pricing is tied to the process of marketing in Norway and to reimbursement in Sweden. Both countries have applied mandatory generic substitution for more than 10 years.

References

  1. Act on Pharmaceutical Benefits (2002: 160) Ministry of Health and Social Affairs, 2002 [in Swedish]Google Scholar
  2. Act on Pharmacy (2000-06-02-39) Ministry of Health and Care Services, 2000 [in Norwegian]Google Scholar
  3. Act on Sales of Medicinal Products (2009:366) Ministry of Health and Social Affairs, 2009 [in Swedish]Google Scholar
  4. Almarsdóttir AB, Morgall JM, Grímsson A (2000) Cost containment of pharmaceutical use in Iceland: the impact of liberalization and user charges. J Health Serv Res Policy 5(2):109–113Google Scholar
  5. Amgros. About Amgros. http://www.amgros.dk/en. Accessed 14 July 2014
  6. Andersson F (1992) Norway’s pivotal role in regulatory health economics and pharmaceutical cost containment—what can other countries learn? Health Policy 21(1):17–34CrossRefGoogle Scholar
  7. Andersson K (2006) Swedish pharmaceutical benefit reforms: analyses of implementation, pharmaceutical sales patterns and expenditures. Göteborg University, GöteborgGoogle Scholar
  8. Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K (2005) What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 14(5):341–348CrossRefGoogle Scholar
  9. Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A (2006) Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 79(2–3):231–243CrossRefGoogle Scholar
  10. Andersson K, Bergström G, Petzold MG, Carlsten A (2007) Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy 81:376–384CrossRefGoogle Scholar
  11. Anell A (2005) Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 75(1):9–17CrossRefGoogle Scholar
  12. Anell A, Glenngård AH, Merkur S (2012) Sweden—health system review. Health Syst Transit 14(5):1–159Google Scholar
  13. Beckman A, Anell A (2013) Changes in health care utilisation following a reform involving choice and privatisation in Swedish primary care: a five-year follow-up of GP-visits. BMC Health Serv Res 13:452CrossRefGoogle Scholar
  14. Bergström G, Karlberg I (2007) Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 81(2–3):358–367CrossRefGoogle Scholar
  15. Bjorvatn A (2012) Making incentives work: hospital organisation and performance. Scand J Public Health 40(5):449–456CrossRefGoogle Scholar
  16. Brekke KR, Straume OR (2003) Pris- og avanseregulering i legemiddelmarkedet: en prinsipiell diskusjon og en vurdering av den norske modellen. Notat 20/2003. Rokkansenteret, Bergen [in Norwegian]Google Scholar
  17. Drummond M, Jönsson B, Rutten F, Stargardt T (2011) Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ 12(3):263–271CrossRefGoogle Scholar
  18. Ess S, Schneeweiss S, Szucs T (2003) European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2):89–103CrossRefGoogle Scholar
  19. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106(2):86–94CrossRefGoogle Scholar
  20. Gerdtham UG, Johannesson M, Gunnarsson B, Marcusson M, Henriksson F (1998) The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics 13(1 Pt 2):127–134CrossRefGoogle Scholar
  21. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL (2009) Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 9(1):65–83CrossRefGoogle Scholar
  22. Grasdal AL, Monstad K (2011) Inequity in the use of physician services in Norway before and after introducing patient lists in primary care. Int J Equity Health 15(10):25CrossRefGoogle Scholar
  23. Hågå A, Sverre JM (2002) Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ 3(3):215–220CrossRefGoogle Scholar
  24. Håkonsen H, Toverud EL (2011) Special challenges for drug adherence following generic substitution for Pakistani immigrants living in Norway. Eur J Clin Pharmacol 67(2):193–201CrossRefGoogle Scholar
  25. Håkonsen H, Horn AM, Toverud EL (2009a) Price control as a strategy for pharmaceutical cost containment—what has been achieved in Norway in the period 1994-2004? Health Policy 90(2–3):277–285CrossRefGoogle Scholar
  26. Håkonsen H, Eilertsen M, Borge H, Toverud EL (2009b) Generic substitution: additional challenge for adherence in hypertensive patients? Curr Med Res Opin 25(10):2515–2521CrossRefGoogle Scholar
  27. Håkonsen H, Hopen HS, Abelsen L, Ek B, Toverud EL (2010) Generic substitution: a potential risk factor for medication errors in hospitals. Adv Ther 27(2):118–126CrossRefGoogle Scholar
  28. HOD (Ministry of Health and Care Services) (2005) White paper no. 18 (2004-2005). Rett kurs mot riktig legemiddelbruk. Legemiddelpolitikken, Oslo [in Norwegian]Google Scholar
  29. Jansson S, Anell A (2006) The impact of decentralised drug-budgets in Sweden—a survey of physicians’ attitudes towards costs and cost-effectiveness. Health Policy 76(3):299–311CrossRefGoogle Scholar
  30. Larsen JB, Vrangbaek K, Traulsen JM (2006) Advocacy coalitions and pharmacy policy in Denmark—solid cores with fuzzy edges. Soc Sci Med 63(1):212–224CrossRefGoogle Scholar
  31. LIS (Drug Procurement Cooperation). About LIS. http://www.lisnorway.no/sider/tekst.asp?id=english. Accessed 14 July 2014
  32. Ljungkvist MO, Andersson D, Gunnarsson B (1997) Cost and utilisation of pharmaceuticals in Sweden. Health Policy 41(Suppl):S55–S69CrossRefGoogle Scholar
  33. LMI (The Norwegian Association of Pharmaceutical Manufacturers) (2005) Facts and figures 2005. http://www.lmi.no/dm_documents/tall_og_fakta_2005_v5_05gsfb2279v5.pdf. Accessed 1 July 2014
  34. LMI (The Norwegian Association of Pharmaceutical Manufacturers) (2014) Facts and figures. http://legemiddelstatistikk.com/2014/index.html. Accessed 1 July 2014
  35. Lundkvist J (2002) Pricing and reimbursement of drugs in Sweden. Eur J Health Econ 3:66–70CrossRefGoogle Scholar
  36. Magnussen J, Vrangbäk K, Saltman RB (2009) Nordic health care systems. Recent reforms and current policy challenges. Open University Press, McGraw Hill, Glasgow. http://www.euro.who.int/__data/assets/pdf_file/0011/98417/E93429.pdf. Accessed 15 July 2014
  37. Milovanovic DR, Pavlovic R, Folic M, Jankovic SM (2004) Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country. Eur J Clin Pharmacol 60(3):149–153CrossRefGoogle Scholar
  38. NoMA (The Norwegian Medicines Agency). Guidelines for pricing. http://www.legemiddelverket.no/Blaa_resept_og_pris/pris-paa-legemidler/maksimalpris/Documents/Retningslinjer%20for%20prisfastsettelse.pdf. Accessed 3 July 2014 [in Norwegian]
  39. Norris P (1998) The impact of European harmonisation on Norwegian drug policy. Health Policy 43(1):65–81CrossRefGoogle Scholar
  40. Persson U, Svensson J, Pettersson B (2012) A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 10(4):217–225CrossRefGoogle Scholar
  41. Regulation on reimbursement of essential medicines etc. (Blåreseptforskriften) (FOR-2007-06-28-814) Ministry of Health and Care Services, 2007 [in Norwegian]Google Scholar
  42. Rudholm N (2008) Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market—consequences for costs and availability. Health Policy 87(2):258–263CrossRefGoogle Scholar
  43. Sandheimer C, Karlberg I (2013) Ten years experience with models for financing of outpatient prescriptions. Health Policy Technol 2(4):188–195CrossRefGoogle Scholar
  44. Socialstyrelsen (2014) Läkemedelsförsäljningen i Sverige - analys och prognos http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19428/2014-4-16.pdf. Accessed 3 July 14 [in Swedish]
  45. Sundar T, Thuestad AB, Thomassen PT, Røshol H, Hjelme K, Andestad U, Bryn E (2006) Reimbursement prescription system in poor state? Tidsskr Nor Laegeforen 126(13):1759–1761 [in Norwegian]Google Scholar
  46. Tordoff JM, Norris PT, Reith DM (2005) Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand? Value Health 8(3):201–208CrossRefGoogle Scholar
  47. Tordoff JM, Norris PT, Reith DM (2008) “Price management” and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals. Value Health 11(7):1214–1226CrossRefGoogle Scholar
  48. Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T (2010) Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94(3):221–229CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.School of PharmacySchool of PharmacyUniversity of OsloOsloNorway
  2. 2.Institute of MedicineUniversity of GothenburgGothenburgSweden

Personalised recommendations